579.50MMarket Cap-4.35P/E (TTM)
10.525High9.900Low346.08KVolume9.900Open10.110Pre Close3.51MTurnover0.63%Turnover RatioLossP/E (Static)57.95MShares13.60052wk High-3.76P/B553.74MFloat Cap2.61252wk Low--Dividend TTM55.37MShs Float30.230Historical High--Div YieldTTM6.18%Amplitude0.920Historical Low10.133Avg Price1Lot Size
Omeros Stock Forum
Omeros’ Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMA
Omeros (OMER) announced successful results from its narsoplimab pivotal trial for treating transplant-associated thrombotic microangiopathy (TA-TMA). The primary statistical analysis showed that patients treated with narsoplimab had an over 3-fold reduction in mortality risk (hazard ratio = 0.32) compared to untreated p...
No comment yet